Capital World Investors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Capital World Investors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,275,000	Closed	-$104M	–	555
2017 Q4	$104M	Hold	2,275,000	–	–	0.02%	286
2017 Q3	$102M	Sell	2,275,000 -150,000	-6%	-$5.11M	0.02%	292
2017 Q2	$72.5M	Buy	2,425,000 +295,000	+14%	+$7.28M	0.02%	316
2017 Q1	$47.3M	Sell	2,130,000 -45,501	-2%	-$976K	0.01%	357
2016 Q4	$41M	Buy	2,175,501 +55,000	+3%	+$1.35M	0.01%	355
2016 Q3	$63.6M	Sell	2,120,501 -1,514,801	-42%	-$47.1M	0.02%	314
2016 Q2	$140M	Sell	3,635,302 -32,199	-0.9%	-$1.34M	0.04%	247
2016 Q1	$140M	Sell	3,667,501 -90,000	-2%	-$3.14M	0.04%	247
2015 Q4	$165M	Hold	3,757,501	–	–	0.05%	247
2015 Q3	$153M	Sell	3,757,501 -25,000	-0.7%	-$1.1M	0.05%	253
2015 Q2	$202M	Buy	3,782,501 +539,250	+17%	+$28.6M	0.05%	250
2015 Q1	$177M	Buy	3,243,251 +836,750	+35%	+$40.6M	0.05%	258
2014 Q4	$107M	Buy	+2,406,501	New	+$108M	0.03%	292

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Capital World Investors's JUNO Position: Q1 2018 in Review

Capital World Investors sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 2,275,000 shares — an estimated $104M sold.

Capital World Investors first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $202M in Q2 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Capital World Investors reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Capital World Investors sold 2,275,000 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $104M.
Capital World Investors first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
Capital World Investors's Juno Therapeutics, Inc. position peaked at $202M in Q2 2015.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Capital World Investors's 13F filing for Q1 2018, filed 15 May 2018.